Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Liujun Anwei Granule is a Traditional Chinese Medicine (TCM) compound preparation developed by Xiyuan Hospital of the China Academy of Chinese Medical Sciences. It is primarily utilized as an adjuvant therapy for patients with colorectal cancer, specifically to manage gastrointestinal side effects associated with chemotherapy, such as nausea, vomiting, and loss of appetite. The formulation is based on the classic 'Liu Jun Zi' decoction, which is traditionally used to tonify the spleen and harmonize the stomach. Clinical research conducted at Xiyuan Hospital has demonstrated its efficacy in reducing chemotherapy-induced nausea and vomiting (CINV) and improving the overall quality of life and nutritional status of cancer patients undergoing treatment regimens like FOLFOX or XELOX.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Liujun Anwei Granule.